Icalcaprant is under clinical development by Cerevel Therapeutics and currently in Phase I for Bipolar I Disorder.

tavapadon for both early and late-stage Parkinson’s disease; and CVL-871 to treat dementia-related apathy. The company is also developing other programs such as CVL-354, PDE4 inhibitor, and M4 Agonist ...

Joe Parkinson leads The Wall Street Journal's world enterprise team, deploying to the world's biggest breaking stories and piloting deeply reported investigations. His stories often follow ...

Earlier this month, the company announced positive results for tavapadon, which met both primary and secondary endpoints in a phase 3 trial for treating early Parkinson's. The company is going to ...

Earlier this month, the company announced positive results for tavapadon, which met both primary and secondary endpoints in a phase 3 trial for treating early Parkinson's. The company is going to ...

London police have made a major development after an Australian backpacker sent a “cryptic” message to a co-worker before vanishing. Jessica Parkinson, from Queensland, was staying at a ...

On 9 December 2024, AbbVie announced positive topline results from its pivotal Phase III TEMPO-2 trial, evaluating tavapadon as a flexible-dose (5mg to 15mg, once daily) monotherapy in early Parkinson ...

Bryan Hill has been aware of Parkinson's disease his whole life. His mother was living with early onset Parkinson's when he was born, and through his adolescence, he did what he could to support her.

Tavapadon is the first and only D1/D5 partial agonist under investigation as a once-daily treatment for Parkinson's disease. The TEMPO-2 trial evaluated the efficacy, safety and tolerability of a ...

Nine senators voted to adopt a resolution to censure the disorderly, sexually explicit gesture Sen. William Parkinson made on session floor earlier this year. Senators Joanne Brown, Chris Barnett, ...